ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 5, 2017

9:00AM-11:00AM
Abstract Number: 23
Auto-Reactive B Cells Escape Peripheral Tolerance Checkpoints in Patients with PR3-ANCA Associated Vasculitis
B Cell Biology and Targets in Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 747
Autoantibodies to Rpp25 (Th/To) Are Specific Markers for Systemic Sclerosis and Are Associated with Limited Cutaneous Disease and Young Age at Disease Onset  
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I
9:00AM-11:00AM
Abstract Number: 130
Availability of Clinical Measures for Patients with Rheumatoid Arthritis in Integrated Delivery Networks Who Receive a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: A Real-World Analysis of an Electronic Health Records Database
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 33
B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus
B Cell Biology and Targets in Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 807
B Cells in Giant Cell Arteritis: a Novel Target for Treatment?
Vasculitis Poster I: Large Vessel Vasculitis
9:00AM-11:00AM
Abstract Number: 40
B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium
B Cell Biology and Targets in Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 35
B-Cell Subset Differences in Inflammatory Rheumatic Diseases
B Cell Biology and Targets in Autoimmune Disease Poster
9:00AM-11:00AM
Abstract Number: 56
Baicalein, a Plant-Derived Small Molecule, Activate Nrf2/Autophagy Signaling Axis Via MEK1/2-ERK1/2-Elk1 Pathway to Suppress the Expression of IL-6 in Human Osteoarthritis Chondrocytes
Biology and Pathology of Bone and Joint Poster I
9:00AM-11:00AM
Abstract Number: 415
Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
9:00AM-11:00AM
Abstract Number: 225
Barriers to the Use of Methotrexate in Ethiopia: Survey of Pharmacy Providers
Healthcare Disparities in Rheumatology Poster
9:00AM-11:00AM
Abstract Number: 436
Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
9:00AM-11:00AM
Abstract Number: 134
Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 672
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 610
Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I
9:00AM-11:00AM
Abstract Number: 412
Baseline Values for Plantar Pressure and Background Characteristics As Indicators for the Limit of Conservative Treatment of Rheumatoid Forefoot Deformity
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response
  • «Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology